AI Article Synopsis
- A comparison of mortality rates between England, Wales, and the US was conducted, focusing on data from 1974-2000.
- Overall mortality rates decreased in all three regions, with England and Wales experiencing a more pronounced decline.
- For more detailed insights, the full paper is available at nursingtimes.net.
Article Abstract
In response to US colleagues' concerns about the NHS, we undertook a comparison of mortality rates in England and Wales and the US. Figures for 1974-2000 were obtained from World Health Organization data on all-cause and cancer mortality rates. Overall rates fell in all three countries but there was a more significant drop in England and Wales over the period. This is a summary: the full paper can be accessed at nursingtimes.net.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bridging thrombolysis versus direct endovascular treatment in acute vertebrobasilar artery complex occlusion.
J Neurosurg
January 2025
1Department of Neurology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui.
Objective: Endovascular treatment (EVT) is an effective treatment for patients with acute vertebrobasilar artery complex occlusion (VBAO). However, the benefit of bridging thrombolysis prior to EVT remains controversial. The purpose of the present study is to explore the best treatment strategy between bridging treatment (BT) and direct EVT in patients with acute VBAO.
View Article and Find Full Text PDFAnalysis of prognosis and medical resource utilization in elderly patients with trauma: A retrospective cohort study in one trauma center.
J Chin Med Assoc
November 2024
Division of Trauma Surgery, Department of Emergency, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
Background: Trauma is consistently among the top ten causes of death worldwide. The aging population, constituting 15.21% of adults aged over 65 in Taiwan as of November 2019, has significantly impacted healthcare expenditures.
View Article and Find Full Text PDFComparison of clinical outcomes in patients with advanced pulmonary sarcomatoid carcinoma treated with immunotherapy-based regimens or chemotherapy: A study based on the SEER database and multicentric real-world settings.
J Cancer Res Ther
December 2024
Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China.
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare lung cancer characterized by early metastasis and invasion. It is predominantly diagnosed at a locally advanced or metastatic stage, hindering the possibility of surgical intervention. However, a standard treatment for advanced PSC remains unestablished.
View Article and Find Full Text PDFComparison between lymph and non-lymph node resection in patients with stage IA non-small-cell lung cancer: A retrospective study.
J Cancer Res Ther
December 2024
No. 2 Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Objective: This retrospective study aimed to determine the need for lymph node resection during surgical treatment in patients with stage IA non-small-cell lung cancer (NSCLC).
Materials And Methods: A total of 1428 patients diagnosed with cT1N0M0 1 A stage NSCLC who underwent surgery were divided into two groups: lymphadenectomy (n = 1324) and nonlymphadenectomy (n = 104). The effects of lymph node resection on overall survival (OS) and recurrence-free survival (RFS) and on clinicopathological factors that affected the prognosis of the patients were investigated.
Clinical features and prognosis analysis of stage III/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective.
J Cancer Res Ther
December 2024
Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China.
Aim: Toripalimab is the first antitumor programmed cell death protein 1 (PD-1) antibody approved in China. For better patient management, it is important to understand the real-world outcomes of toripalimab in treating patients with lung cancer in the real world outside of clinical trials to improve patient care.
Methods: We retrospectively examined the clinical data of 80 patients with lung cancer who received the PD-1 inhibitor (toripalimab).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!